Pharmaceuticals US

US In Vivo CAR-T Therapy Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US In Vivo CAR-T Therapy Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $31.4 Mn Placeholder estimate
Estimate 2025 $46.6 Mn 41.4% of the global market
Projected 2034 $1.62 Bn 3,369.5% Adds $1.57 Bn over 9 forecast years
CAGR 2025–2034 48.3% Faster than 99% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • US is 41.44% of the global market.
  • In North America, the largest is US (this report) at $46.6 Mn.
  • Fastest growing: Canada at 49.7% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.57 Bn total, 2026–2034

Year-by-year market size, 2024–2034
In Vivo CAR-T Therapy Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $31.4 Mn — —
2025 (base) $46.6 Mn +$15.2 Mn —
2026 (forecast) $69.1 Mn +$22.5 Mn +48.3%
2027 (forecast) $102.5 Mn +$33.4 Mn +119.9%
2028 (forecast) $152.1 Mn +$49.5 Mn +226.2%
2029 (forecast) $225.5 Mn +$73.4 Mn +383.7%
2030 (forecast) $334.4 Mn +$108.9 Mn +617.3%
2031 (forecast) $496.0 Mn +$161.5 Mn +963.8%
2032 (forecast) $735.5 Mn +$239.6 Mn +1,477.6%
2033 (forecast) $1.09 Bn +$355.3 Mn +2,239.5%
2034 (forecast) $1.62 Bn +$526.9 Mn +3,369.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US In Vivo CAR-T Therapy Market Analysis at a glance
Market size, 2025$46.6 Mn placeholder estimate
Forecast, 2034$1.62 Bn placeholder estimate
Growth (CAGR), 2025–203448.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDelivery, indication and end user (see all)
Key playersCapstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics, EsoBiotec (AstraZeneca) (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials3 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US In Vivo CAR-T Therapy Market Analysis Executive Summary

In vivo CAR-T therapy delivers instructions straight into the body so a patient's own T cells become cancer fighters, without lab manufacturing.

Key segments of the in Vivo CAR-T Therapy market include delivery (Lentiviral Vectors, Lipid Nanoparticles and Targeted Viral Vectors) and indication (Blood Cancers, Autoimmune Diseases and Solid Tumors).

Bar chart: US In Vivo CAR-T Therapy market size, 2024–2034, placeholder estimates. $31.4 Mn in 2024, $46.6 Mn in 2025 and $1.62 Bn in 2034, 48.3% CAGR.
US In Vivo CAR-T Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US In Vivo CAR-T Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the in Vivo CAR-T Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the in Vivo CAR-T Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for In Vivo CAR-T Therapy Market in US

The in Vivo CAR-T Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for In Vivo CAR-T Therapy Market in US

In Vivo CAR-T Therapy in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 3 studies on In Vivo CAR-T Therapy that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for in Vivo CAR-T Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in In Vivo CAR-T Therapy right now, from free public sources.

Clinical trials

3 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Chongqing Precision Biotech Co., Ltd 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

In Vivo CAR-T Therapy in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the In Vivo CAR-T Therapy market in the US?
Placeholder estimate: about $46.6 Mn in 2025, rising to about $1.62 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the In Vivo CAR-T Therapy market in the US growing?
Placeholder estimate: about 48.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the In Vivo CAR-T Therapy market report cover?
The report splits the market by delivery (Lentiviral Vectors, Lipid Nanoparticles, Targeted Viral Vectors), indication (Blood Cancers, Autoimmune Diseases, Solid Tumors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the In Vivo CAR-T Therapy market?
Key players include Capstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics and EsoBiotec (AstraZeneca).
What is driving the In Vivo CAR-T Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
Who regulates In Vivo CAR-T Therapy in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on In Vivo CAR-T Therapy are running in the US?
3 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on In Vivo CAR-T Therapy?
PubMed lists 24 papers on In Vivo CAR-T Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on cell and gene therapy and oncology

See the topic